Asian Spectator


The Times

.

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach News...

Hisense Celebrates Mother's Day, Making Every Moment Incredibl...

QINGDAO, China, May 9, 2022 /PRNewswire-AsiaNet/ -- Mothers are the heart of every family, giving support to their families and enabling every family member to have a joyful life. On Mother...

Watsons Launches Exclusive IP The Watsons Family Across Asia to Drive Customer Engagement Brand Loyalty

HONG KONG SAR - Media OutReach Newswire - 17 September 2025 - Watsons, AS Watson Group's flagship health and beauty brand, announces the exclusive launch of "The Watsons Family" - an innova...

Real estate start-up RuListing posts record growth, looks to i...

TORONTO, Nov. 5, 2018 /PRNewswire-AsiaNet/ - Real estate disruptor, www.RuListing.com soared across the U.S., Australia and Canada, as Founder Susan Joynt ( https://ca.linkedin.com/in/susanj...

Inovio Demonstrates 80% 6-Month Progression-Free Survival In P...

PLYMOUTH MEETING, Pennsylvania, Nov. 5, 2019 /PRNewswire-AsiaNet/ -- -- 80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 MonthsInovio Pharmaceut...

App Annie is now data.ai - the 1st Unified Data AI company

SAN FRANCISCO, Feb. 16, 2022 /PRNewswire-AsiaNet/ -- App Annie has changed its name to data.ai, establishing a big enterprise market opportunity: "Unified Data AI".Logo - https://mma.prnewsw...

Russian-speaking APTs Turla and Sofacy share malware delivery,...

MELBOURNE, Australia, Oct. 11, 2018/PRNewswire-AsiaNet/-- Kaspersky Lab Global Research & Analysis Team(GReAT) monitoring the various clusters of the long standing, Russian-speaking thre...

Shanghai Electric Strengthens Environmental, Social, and Corpo...

SHANGHAI, Jan. 21, 2021 /PRNewswire-AsiaNet/ -- Shanghai Electric Group ("Shanghai Electric" or "the Company") has strengthened its environmental, social, and corporate governance for the Ph...

Tableau Expands Data Prep Capabilities with Tableau Prep Condu...

SEATTLE, Feb. 13, 2019 /PRNewswire-AsiaNet/ -- Latest data preparation product is part of thenew Tableau Data Management Add-OnTableau Software (NYSE: DATA), the leading analytics platform...

Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium

Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium

TOKYO, Dec 5, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest information on its in-house discovered and developed eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN, "eribulin") will be presented during the 42nd San Antonio Breast Cancer Symposium (SABCS2019). The symposium will be held from December 10 through 14, 2019, in San Antonio, Texas in the United States.

Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium

A total of five poster presentations will be given at this year's SABCS including the study results evaluating absolute lymphocyte count at the baseline with eribulin as a predictor of overall survival from the post-hoc analysis of two Phase III clinical studies of eribulin in patients with advanced or metastatic breast cancer.Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Copyright 2019 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girişStreamEastStreamEastjojobetcialis 20 mg fiyat